Mumbai-based private equity firm Somerset Indus Capital Partners today announced the successful fund raise of its third fund, Fund III, at $288 million, exceeding its initial tarobtain of $250 million.
The oversubscribed saw conviction from both existing and new Limited Partners for Somerset’s differentiated healthcare-focutilized, impact-aligned investment strategy.
The firm declared that the fund witnessed participation from a diverse group of global institutional investors, including Development Finance Institutions (DFIs), global investment firms, domestic financial institutions, insurance companies, funds of funds, family offices, and impact investors across Europe, the United States and South-East Asia.
With Fund III, Somerset will continue to focus on addressing healthcare access gaps across India’s “missing middle,” particularly in Tier II and Tier III markets. The fund will invest in scalable healthcare businesses delivering affordable, accessible quality care across healthcare delivery, pharmaceuticals, medical devices, diagnostics, and allied sectors.
“The successful fund raise is a strong finishorsement of our strategy and execution capabilities. We are grateful for the continued trust of our Limited Partners who share our conviction that impact and financial performance can be mutually reinforcing,” declared Avinash Kenkare, Partner, Somerset Indus Capital Partners.
“India’s healthcare ecosystem is undergoing a structural transformation, particularly beyond the metros. Fund III positions us to deepen our presence in underserved markets and partner with entrepreneurs building scalable healthcare platforms. We remain committed to delivering measurable impact alongside sustainable financial returns,” added Mayur Sirdesai, Partner, Somerset Indus Capital Partners.
Somerset typically invests between $15 million and $40 million per portfolio company. However, through co-investment syndication alongside its strong LP network, the firm has the flexibility to participate in significantly larger transactions in the range of $60-80 million.
The additional capital will enable it to support larger and more structurally transformative opportunities across areas such as preventive care and OPD-linked insurance, healthcare financing, embedded insurance solutions, value-driven generics, India-focutilized medtech innovation, and diagnostics platforms improving accessibility and standardisation beyond metro markets.
Through fund III, Somerset has built three investments, i.e. Cyrix Healthcare (MedTech servicing), Printmann Offset (pharmaceutical packaging), and NU Hospitals (a nephrology and urology focutilized single-specialty hospital chain).
Leave a Reply